icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
San Francisco
November 2018
Back grey_arrow_rt.gif
The Hepatitis C Continuum of Care for People Who Inject Drugs; Philadelphia, PA - young PWID 8% treated for HCV, older still only 25%
  Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Eman Addish, MPH1, Kendra Viner, MPH, PhD1, Stacey Trooskin, MD, PhD2, Jay Kostman, MD2 , Hannah Zellman, MSW3
Caroline C. Johnson, MD1, Danica Kuncio, MPH1
1 Philadelphia Department of Public Health; 2 Philadelphia FIGHT Community Health Centers, ; 3 Health Federation of Philadelphia


ALSO AT AASLD ------------------------------------------------
AASLD: Changing Cascade of Care for Hepatitis C in the Era of Direct-Acting Antivirals - (11/13/18)
"Even by 2030, the cure rate among non-NHANES population is projected to remain extremely low at 4%.....Furthermore, whereas the treatment rate increased substantially in the NHANES population from 2010 to 2018 (more than doubles from 27% to 61%), it only increased from 0% to 3% in non-NHANES....Among different subpopulation, HCV treatment rates would remain lowest in incarcerated population at <1%.....Implementing universal HCV screening in all populations will have the biggest impact on improving the cascade of care..... Despite the availability of DAAs, by 2030, under current screening and treatment practice, only 68% people will become aware of their HCV and 49% of all HCV people will receive treatment...."
AASLD: Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. - (11/13/18)
MAJORITY with HCV not treated (Medicare, commercial database): 27,596 with HCV in database: only 79000 treated but 18,000 NOT TREATED